Speaker Profile
M.D., Chief Medical Officer, Immuno-Oncology, BeiGene
Biography
Dr. Amy C. Peterson, M.D. has been Chief Medical Officer of Immuno-Oncology at BeiGene, Ltd. since August 2016. Dr. Peterson will lead the global clinical development of BGB-A317, a PD-1 inhibitor; BGB-290, a PARP inhibitor and the expanding pipeline of other immuno-oncology agents expected to enter clinical development. Dr. Peterson expands BeiGenes senior medical leadership in response to emerging global development opportunities, particularly in immuno-oncology. She has broad experience in oncology drug development and academic background in immuno-oncology research. Prior to joining BeiGene, Dr. Peterson was Vice President of Clinical Development at Medivation, where she was primarily responsible for the development of enzalutamide and talazoparib in breast cancer and of pidilizumab in diffuse large b-cell lymphoma. Previously, she served as Associate Group Medical Director at Genentech, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology. Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski. Dr. Peterson received her M.D. from Thomas Jefferson University in Philadelphia, PA and she completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago. She holds a Bachelor of Arts degree from Wesleyan University in Middletown, CT.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: We have very effective immune checkpoint inhibitors targeting molecules like PD-1 or CTLA-4, and undoubtedly this class of inhibitors and their combination has laid the foundation for the described success in the clinic. This session will explore effective combination immunotherapies, biomarker development, understanding the mechanism of action, and the progress and future prospects of combinations, both with established treatment options and novel modalities and targets.
